Risk Factors Update Summary
- Incurred net loss increased from $64.0 million in 2022 to $123.4 million in 2023.
- Potential payments from collaborations limited due to termination with Takeda and Roche.
- Accumulated deficit rose from $470 million to $594 million as of December 31, 2023.
- Transitioned manufacturing from external CMOs to clinical facility, becoming sole supplier for clinical materials.
- Cash, cash equivalents, and short-term investments decreased from $282 million to $212 million.
- Increased employee count from 314 to 330 as research and development activities expanded.
- Clinical development focus shifted from P-BCMA-ALLO1 to P-MUC1C-ALLO1 and P-CD19CD20-ALLO1.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1661460&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.